drugset
drugset / Trial / NCT01470716

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

NCT01470716 ↗

Phase 2 Unknown 26 enrolled National Cancer Center, Korea Hoffmann-La Roche · collab
NaSingle-groupOpen-labelTreatment

Summary

This study examines preoperative Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations.

Timeline

Start
2012-01
Primary completion
2021-12-31
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule — Oral

Indications

non-small cell lung carcinoma